Compile Data Set for Download or QSAR
Report error Found 595 for UniProtKB: P25322
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 6.18nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395784(US10308654, Example 12)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395785(US10308654, Example 13)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395786(US10308654, Example 14)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395787(US10308654, Example 15)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395788(US10308654, Example 16)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395789(US10308654, Example 17)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395790(US10308654, Example 18)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395791(US10308654, Example 19)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395792(US10308654, Example 20)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395793(US10308654, Example 21)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395795(US10308654, Example 23)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395796(US10308654, Example 24)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395797(US10308654, Example 25)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395798(US10308654, Example 26)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395799(US10308654, Example 27)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395801(US10308654, Example 29)
Affinity DataIC50: 10nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676342(US20240166635, Example 63)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676344(US20240166635, Example 64b)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676432(US20240166635, Example 125a | US20240166635, Examp...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676212(US20240166635, Example 3b | US20240166635, Example...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676213(US20240166635, Example 4a)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676233(US20240166635, Example 7a)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676276(US20240166635, Example 24a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676301(US20240166635, Example 38a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676303(US20240166635, Example 39a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676305(US20240166635, Example 40a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676307(US20240166635, Example 41a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676313(US20240166635, Example 44a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676317(US20240166635, Example 46a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676319(US20240166635, Example 47a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676321(US20240166635, Example 48a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676323(US20240166635, Example 49a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676327(US20240166635, Example 50a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676331(US20240166635, Example 52)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676333(US20240166635, Example 54)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676336(US20240166635, Example 57)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622513(US20230312583, Compound I-9)
Affinity DataIC50: 22.5nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622518(US20230312583, Compound I-14)
Affinity DataIC50: 23.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622506(US20230312583, Compound I-2)
Affinity DataIC50: 30.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395794(US10308654, Example 22)
Affinity DataIC50: 55nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Changzhou Longthera Pharmaceuticals

US Patent
LigandPNGBDBM395800(US10308654, Example 28)
Affinity DataIC50: 55nMAssay Description:The test compound was dissolved in dimethyl sulfoxide and the solution was diluted to each concentration gradient with a buffer (50 mM HEPES, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676340(US20240166635, Example 61)
Affinity DataIC50: 55nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676341(US20240166635, Example 62)
Affinity DataIC50: 55nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676343(US20240166635, Example 64a)
Affinity DataIC50: 55nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676348(US20240166635, Example 68)
Affinity DataIC50: 55nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676378(US20240166635, Example 98)
Affinity DataIC50: 55nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676379(US20240166635, Example 99a)
Affinity DataIC50: 55nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676391(US20240166635, Example 104a)
Affinity DataIC50: 55nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM676393(US20240166635, Example 105a | US20240166635, Examp...)
Affinity DataIC50: 55nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 595 total ) | Next | Last >>
Jump to: